Imlunestrant was effective in combination with abemaciclib, and as monotherapy in ESR1-mutated breast cancer SAN ANTONIO – Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free survival in patients with endocrine therapy-pretreated, ER-positive, HER2-negative advanced breast cancer—as monotherapy in patients withESR1mutations and as combination therapy with abemaciclib (Verzenio) in all patients, regardless of ESR1 … Continue reading Next-generation SERD Protects Against Progression in Some Patients With Advanced Breast Cancer Resistant to Standard Hormone Therapy